Cargando…
Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
INTRODUCTION: People living with HIV (PLWH) are mainly African or Asian, the majority female. In contrast, pharmaceutical companies typically conduct phase 3 regulatory randomised controlled trials (RCTs) in high-income countries (HICs), where PLWH are mainly white males. Regulatory authorities can...
Autores principales: | Pepperrell, Toby, Hill, Andrew, Moorhouse, Michelle, Clayden, Polly, McCann, Kaitlyn, Sokhela, Simiso, Serenata, Celicia, Venter, Willem Daniel Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mediscript Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213067/ https://www.ncbi.nlm.nih.gov/pubmed/32405424 |
Ejemplares similares
-
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen
por: Venter, Willem D.F., et al.
Publicado: (2017) -
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?
por: Fairlie, Lee, et al.
Publicado: (2019) -
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
por: Tovar Sanchez, Tamara, et al.
Publicado: (2023) -
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020) -
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
por: Chandiwana, Nomathemba C., et al.
Publicado: (2021)